Mobile

A randomised, placebo-controlled, double-blind, double-dummy, crossover study to assess the onset of action of two inhalations of Symbicort 160/4.5μg compared with two inhalations of Seretide 25/250μ...

Update Il y a 5 ans
Reference: EUCTR2004-001724-20

A randomised, placebo-controlled, double-blind, double-dummy, crossover study to assess the onset of action of two inhalations of Symbicort 160/4.5μg compared with two inhalations of Seretide 25/250μg, two inhalations of Ventoline 100μg, and placebo, delivered by pressurised metered dose inhalers, in patients with chronic obstructive pulmonary disease (COPD)

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To evaluate efficacy i.e. to study the bronchodilatating effect within the first 180 minutes after two inhalations of Symbicort 160/4.5μg compared with two inhalations of Seretide 25/250μg, two inhalations of Ventoline 100μg, and placebo, delivered by pressurised metered dose inhalers, in patients with chronic obstructive pulmonary disease (COPD).

Inclusion criteria

  • This is an application for a phase III study to be conducted in COPD patients

Links